New insider activity at Insmed ( (INSM) ) has taken place on August 21, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent series of transactions involving Insmed stock, COO Roger Adsett sold 25,000 shares, amounting to a total of $3,189,585. Additionally, Director Melvin Sharoky parted with 10,000 shares, generating $1,295,000 from the sale. These significant sales highlight notable movements within the company’s stock holdings.
Recent Updates on INSM stock
In the last 24 hours, Insmed has seen significant developments impacting its stock valuation. William Blair initiated coverage with an Outperform rating, citing potential valuation increases from the clinical and commercial execution of Brinsupri, Arikayce, and TPIP. Stifel and Truist raised their price targets, driven by the anticipated strong commercial launch of Brinsupri. H.C. Wainwright doubled its target due to the ‘pipeline-in-a-pill’ potential. However, Morgan Stanley downgraded Insmed to Equal Weight, despite raising its price target, due to the belief that the current valuation already reflects the near-term opportunities of Brinsupri. Insmed’s Q2 earnings call highlighted record ARIKAYCE revenue and successful capital raising, although concerns remain about the brensocatib launch and uncertainties in certain trials. Overall, Insmed’s strong late-stage portfolio performance and strategic advancements have positioned it well for future growth, despite some challenges.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s overall stock score is driven by strong technical momentum and positive corporate events, including FDA approval and promising clinical trial results. However, significant financial challenges and valuation concerns weigh heavily on the score. The earnings call provided a positive outlook, but the company’s financial health remains a critical risk factor.
To see Spark’s full report on INSM stock, click here.
More about Insmed
YTD Price Performance: 85.06%
Average Trading Volume: 3,921,344
Technical Sentiment Signal: Buy
Current Market Cap: $26.89B